{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:20:24Z","timestamp":1760235624885,"version":"build-2065373602"},"reference-count":94,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The following main treatment approaches are currently used in locally advanced adenocarcinomas of the oesophagus and gastrooesophageal junction (GOJ): preoperative chemoradiotherapy and surgery, and perioperative chemotherapy and surgery. While preoperative chemoradiotherapy is used primarily in oesophageal tumours, perioperative chemotherapy is the treatment of choice in Western countries for gastric cancer. The optimal treatment strategy for GOJ adenocarcinoma is still not clear. In comparison to other malignancies, biomarkers are used as predictive factors in distal oesophageal and GOJ adenocarcinomas in a very limited way, and moreover, only in metastatic stages (e.g., HER2 status, or microsatellite instability status). The aim of the article is to provide an overview of current treatment options in locally advanced adenocarcinomas of oesophagus and GOJ based on the latest evidence, including the possible potential of predictive biomarkers in optimizing treatment.<\/jats:p>","DOI":"10.3390\/cancers13184591","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T21:37:12Z","timestamp":1631569032000},"page":"4591","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined Therapy of Locally Advanced Oesophageal and Gastro\u2013Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6497-7505","authenticated-orcid":false,"given":"Milan","family":"Vo\u0161mik","sequence":"first","affiliation":[{"name":"Department of Oncology and Radiotherapy, Charles University, Faculty of Medicine in Hradec Kr\u00e1lov\u00e9 and University Hospital Hradec Kr\u00e1lov\u00e9, 500 05 Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jind\u0159ich","family":"Kopeck\u00fd","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, Charles University, Faculty of Medicine in Hradec Kr\u00e1lov\u00e9 and University Hospital Hradec Kr\u00e1lov\u00e9, 500 05 Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislav","family":"John","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, Charles University, Faculty of Medicine in Hradec Kr\u00e1lov\u00e9 and University Hospital Hradec Kr\u00e1lov\u00e9, 500 05 Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2105-625X","authenticated-orcid":false,"given":"Ond\u0159ej","family":"Kube\u010dek","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, Charles University, Faculty of Medicine in Hradec Kr\u00e1lov\u00e9 and University Hospital Hradec Kr\u00e1lov\u00e9, 500 05 Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5789-8152","authenticated-orcid":false,"given":"Petr","family":"Lochman","sequence":"additional","affiliation":[{"name":"Department of Surgery, Charles University, Faculty of Medicine in Hradec Kr\u00e1lov\u00e9 and University Hospital Hradec Kr\u00e1lov\u00e9, 500 05 Hradec Kr\u00e1lov\u00e9, Czech Republic"},{"name":"Department of Field Surgery, Faculty of Military Health Sciences, University of Defence, 500 05 Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aml Mustafa","family":"Banni","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, Charles University, Faculty of Medicine in Hradec Kr\u00e1lov\u00e9 and University Hospital Hradec Kr\u00e1lov\u00e9, 500 05 Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libor","family":"Hru\u0161ka","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, Charles University, Faculty of Medicine in Hradec Kr\u00e1lov\u00e9 and University Hospital Hradec Kr\u00e1lov\u00e9, 500 05 Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5972-3866","authenticated-orcid":false,"given":"Igor","family":"Sir\u00e1k","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, Charles University, Faculty of Medicine in Hradec Kr\u00e1lov\u00e9 and University Hospital Hradec Kr\u00e1lov\u00e9, 500 05 Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/gastro\/goab010","article-title":"Gastrointestinal cancers in China, the USA, and Europe","volume":"9","author":"Xie","year":"2021","journal-title":"Gastroenterol. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jnci\/dji024","article-title":"The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence","volume":"97","author":"Pohl","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"doi-asserted-by":"crossref","unstructured":"Kort, E.J., Sevensma, E., and Fitzgerald, T.L. (2009). Trends in esophageal cancer and body mass index by race and gender in the state of Michigan. BMC Gastroenterol., 9.","key":"ref_3","DOI":"10.1186\/1471-230X-9-47"},{"doi-asserted-by":"crossref","unstructured":"Marabotto, E., Pellegatta, G., Sheijani, A.D., Ziola, S., Zentilin, P., De Marzo, M.G., Giannini, E.G., Ghisa, M., Barberio, B., and Scarpa, M. (2021). Prevention Strategies for Esophageal Cancer-An Expert Review. Cancers, 13.","key":"ref_4","DOI":"10.3390\/cancers13092183"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1007\/s12328-020-01237-x","article-title":"Epidemiology of esophageal cancer: Update in global trends, etiology and risk factors","volume":"13","author":"Uhlenhopp","year":"2020","journal-title":"Clin. J. Gastroenterol."},{"key":"ref_6","first-page":"25","article-title":"Cardia cancer: Attempt at a therapeutically relevant classification","volume":"58","author":"Siewert","year":"1987","journal-title":"Der Chir. Z. Geb. Oper. Medizen"},{"key":"ref_7","first-page":"173","article-title":"Carcinoma of the cardia: Carcinoma of the gastroesophageal junction-classification, pathology and extent of resection","volume":"9","author":"Siewert","year":"1996","journal-title":"Dis. Esophagus"},{"doi-asserted-by":"crossref","unstructured":"Sobin, L.H., and Wittekind, C. (2009). In TNM Classification of Malignant Tumours, Wiley-Blackwell. [6th ed.].","key":"ref_8","DOI":"10.1002\/9780471420194.tnmc26"},{"doi-asserted-by":"crossref","unstructured":"Sobin, L.H., Gospodarowicz, M.K., and Wittekind, C. (2009). In TNM Classification of Malignant Tumours, Wiley-Blackwell. [7th ed.].","key":"ref_9","DOI":"10.1002\/9780471420194.tnmc26"},{"doi-asserted-by":"crossref","unstructured":"Brierley, J.D., Gospodarowicz, M.K., and Wittekind, C. (2017). In TNM Classification of Malignant Tumours, Wiley-Blackwell. [8th ed.].","key":"ref_10","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/SLA.0000000000003499","article-title":"Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study","volume":"274","author":"Kurokawa","year":"2021","journal-title":"Ann. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"v50","DOI":"10.1093\/annonc\/mdw329","article-title":"Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Lordick","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1200\/JCO.20.00866","article-title":"Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline","volume":"38","author":"Shah","year":"2020","journal-title":"J. Clin. Oncol."},{"unstructured":"(2020, June 09). NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines Version 2. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/esophageal.pdf.","key":"ref_14"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_16","first-page":"1623","article-title":"Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85\u201301)","volume":"281","author":"Cooper","year":"1999","journal-title":"Radiat. Ther. Oncol. Group. JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","article-title":"INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy","volume":"20","author":"Minsky","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9610(03)00066-7","article-title":"A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer","volume":"185","author":"Urschel","year":"2003","journal-title":"Am. J. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/gut.2003.025080","article-title":"Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and meta-analysis","volume":"53","author":"Fiorica","year":"2004","journal-title":"Gut"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1470-2045(07)70039-6","article-title":"Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A metaanalysis","volume":"8","author":"Gebski","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1056\/NEJM199608153350702","article-title":"A comparison of multimodal therapy and surgery for esophageal adenocarcinoma","volume":"335","author":"Walsh","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1442-2050.2002.00214.x","article-title":"Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival","volume":"15","author":"Walsh","year":"2002","journal-title":"Dis. Esophagus"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1200\/JCO.2001.19.2.305","article-title":"Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma","volume":"19","author":"Urba","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(05)70288-6","article-title":"Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial","volume":"6","author":"Burmeister","year":"2005","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1200\/JCO.2007.12.9593","article-title":"Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781","volume":"26","author":"Tepper","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"Hulshof","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1200\/JCO.20.03614","article-title":"Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial","volume":"39","author":"Eyck","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa010187","article-title":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","volume":"345","author":"Macdonald","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2011.36.7136","article-title":"Updated analysis of SWOG-directed intergroup study 0116: A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection","volume":"30","author":"Smalley","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1200\/JCO.2017.74.2130","article-title":"Adjuvant Chemoradiotherapy with Epirubicin, Cisplatin, and Fluorouracil Compared with Adjuvant Chemoradiotherapy with Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance)","volume":"35","author":"Fuchs","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial","volume":"29","author":"Ychou","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2\/3 trial","volume":"393","author":"Homann","year":"2019","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","article-title":"Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer","volume":"27","author":"Allum","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJM199812313392704","article-title":"Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer","volume":"339","author":"Kelsen","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S1470-2045(17)30447-3","article-title":"Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): An open-label, randomised phase 3 trial","volume":"18","author":"Alderson","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1200\/JCO.2011.36.5908","article-title":"Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer","volume":"29","author":"Sasako","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","article-title":"CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial","volume":"15","author":"Noh","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","article-title":"CRITICS investigators; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): An international, open-label, randomised phase 3 trial","volume":"19","author":"Cats","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2008.17.0506","article-title":"Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction","volume":"27","author":"Stahl","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ejca.2017.04.027","article-title":"Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial","volume":"81","author":"Stahl","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.2021.39.15_suppl.4004","article-title":"Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol)","volume":"39","author":"Reynolds","year":"2021","journal-title":"J. Clin. Oncol."},{"doi-asserted-by":"crossref","unstructured":"Hoeppner, J., Lordick, F., Brunner, T., Glatz, T., Bronsert, P., R\u00f6thling, N., Schmoor, C., Lorenz, D., Ell, C., and Hopt, U.T. (2016). ESOPEC: Prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer, 16.","key":"ref_44","DOI":"10.1186\/s12885-016-2564-y"},{"doi-asserted-by":"crossref","unstructured":"Leong, T., Smithers, B.M., Michael, M., Gebski, V., Boussioutas, A., Miller, D., Simes, J., Zalcberg, J., Haustermans, K., and Lordick, F. (2015). TOPGEAR: A randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG\/TROG\/EORTC\/NCIC CTG). BMC Cancer., 15.","key":"ref_45","DOI":"10.1186\/s12885-015-1529-x"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1245\/s10434-017-5830-6","article-title":"TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG","volume":"24","author":"Leong","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1470-2045(17)30043-8","article-title":"Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): Primary analysis results of a multicentre, open-label, randomised phase 2\u20133 trial","volume":"18","author":"Cunningham","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2020.38.15_suppl.4500","article-title":"Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology\/RTOG 1010","volume":"38","author":"Safran","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/JCO.2020.38.15_suppl.4502","article-title":"Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO","volume":"38","author":"Hofheinz","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S1470-2045(18)30481-9","article-title":"Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): Final analysis of a double-blind, randomised, placebo-controlled phase 3 study","volume":"19","author":"Tabernero","year":"2018","journal-title":"Lancet Oncol."},{"doi-asserted-by":"crossref","unstructured":"Wagner, A.D., Grabsch, H.I., Mauer, M., Marreaud, S., Caballero, C., Thuss-Patience, P., Mueller, L., Elme, A., Moehler, M.H., and Martens, U. (2019). EORTC-1203-GITCG-the \u201cINNOVATION\u201d-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: A randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer, 19.","key":"ref_52","DOI":"10.1186\/s12885-019-5675-4"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1200\/JCO.2020.38.15_suppl.4549","article-title":"Interim safety analysis of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma\u2014A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK","volume":"38","author":"Homann","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2217\/fon-2018-0581","article-title":"KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer","volume":"15","author":"Bang","year":"2019","journal-title":"Future Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3389\/fonc.2019.01320","article-title":"VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and\/or R1): An Open Label Randomized Controlled Phase-2-Study","volume":"9","author":"Smyth","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pathol.2020.10.007","article-title":"Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: A guide to immunohistochemistry implementation and interpretation","volume":"53","author":"Paver","year":"2021","journal-title":"Pathology"},{"doi-asserted-by":"crossref","unstructured":"Park, R., Da Silva, L.L., and Saeed, A. (2021). Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond. Cancers, 13.","key":"ref_57","DOI":"10.3390\/cancers13071715"},{"doi-asserted-by":"crossref","unstructured":"H\u00f6gner, A., and Thuss-Patience, P. (2021). Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma. Pharmaceuticals, 14.","key":"ref_58","DOI":"10.3390\/ph14020151"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 Trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1245\/s10434-015-4931-3","article-title":"Strong prognostic value of microsatellite instability in intestinal type non-cardia gastric cancer","volume":"23","author":"Marrelli","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/ijc.32030","article-title":"Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy","volume":"144","author":"Haag","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10120-018-00918-4","article-title":"Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer","volume":"22","author":"Hashimoto","year":"2019","journal-title":"Gastric Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ijc.29449","article-title":"The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses","volume":"137","author":"Kim","year":"2015","journal-title":"Int. J. Cancer."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.surg.2005.08.021","article-title":"Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers","volume":"139","author":"Beghelli","year":"2006","journal-title":"Surgery"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE061): A randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1245\/s10434-009-0580-8","article-title":"Chemosensitivity and survival in gastric cancer patients with microsatellite instability","volume":"16","author":"Oki","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000499628","article-title":"Prognostic impact of microsatellite instability in Asian gastric cancer patients enrolled in the ARTIST trial","volume":"97","author":"Miceli","year":"2019","journal-title":"Oncology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1053\/gast.1996.v110.pm8536886","article-title":"Microsatellite instability at multiple loci in gastric carcinoma: Clinicopathologic implications and prognosis","volume":"110","author":"Seruca","year":"1996","journal-title":"Gastroenterology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s00268-012-1652-7","article-title":"Microsatellite instability is associated with a better prognosis for gastric cancer patients after curative surgery","volume":"36","author":"Fang","year":"2012","journal-title":"World J. Surg."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3892\/mco.2015.506","article-title":"Microsatellite instability and survival in gastric cancer: A systematic review and meta-analysis","volume":"3","author":"Zhu","year":"2015","journal-title":"Mol. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jso.23618","article-title":"Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis","volume":"110","author":"Choi","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","article-title":"Mismatch repair deficiency, microsatellite instability, and survival: An exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial","volume":"3","author":"Smyth","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/SLA.0000000000002803","article-title":"Microsatellite instability and programmed cell death-ligand 1 expression in stage II\/III gastric cancer: Post hoc analysis of the CLASSIC randomized controlled study","volume":"270","author":"Choi","year":"2019","journal-title":"Ann. Surg."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.19.01124","article-title":"Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer","volume":"37","author":"Pietrantonio","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1470-2045(20)30025-5","article-title":"Chemotherapy for resectable microsatellite instability-high gastric cancer?","volume":"21","author":"Smyth","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_78","first-page":"769","article-title":"Epstein-Barr virus-associated gastric adenocarcinoma","volume":"140","author":"Shibata","year":"1992","journal-title":"Am. J. Pathol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.molonc.2016.09.004","article-title":"Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer","volume":"10","author":"Dai","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat. Med."},{"doi-asserted-by":"crossref","unstructured":"Stanland, L.J., and Luftig, M.A. (2020). The Role of EBV-Induced Hypermethylation in Gastric Cancer Tumorigenesis. Viruses, 12.","key":"ref_81","DOI":"10.3390\/v12111222"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s12272-017-0939-5","article-title":"DNA hypermethylation induced by Epstein-Barr virus in the development of Epstein-Barr virus-associated gastric carcinoma","volume":"40","author":"Choi","year":"2017","journal-title":"Arch. Pharm. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.33213","article-title":"Morphologic and molecular analysis of early-onset gastric cancer","volume":"127","author":"Setia","year":"2020","journal-title":"Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/gcc.22683","article-title":"Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type","volume":"58","author":"Koh","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"doi-asserted-by":"crossref","unstructured":"Grosser, B., Kohlruss, M., Slotta-Huspenina, J., Jesinghaus, M., Pfarr, N., Steiger, K., Novotny, A., Gaida, M.M., Schmidt, T., and Hapfelmeier, A. (2020). Impact of Tumor Localization and Molecular Subtypes on the Prognostic and Predictive Significance of p53 Expression in Gastric Cancer. Cancers, 12.","key":"ref_85","DOI":"10.3390\/cancers12061689"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"41","DOI":"10.14712\/fb2018064020041","article-title":"HPV Status and Mutation Analysis Using Multiparallel Sequencing in Distal Oesophageal and Gastro-oesophageal Junction Adenocarcinomas","volume":"64","author":"Laco","year":"2018","journal-title":"Folia Biol."},{"doi-asserted-by":"crossref","unstructured":"Schulz-Heddergott, R., and Moll, U.M. (2018). Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target. Cancers, 10.","key":"ref_87","DOI":"10.3390\/cancers10060188"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"595187","DOI":"10.3389\/fonc.2020.595187","article-title":"Mutant p53 in Cancer Progression and Targeted Therapies","volume":"10","author":"Zhu","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/annonc\/mdg486","article-title":"The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: From the laboratory to clinical practice","volume":"14","author":"Graziano","year":"2003","journal-title":"Ann Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"689139","DOI":"10.3389\/fmolb.2021.689139","article-title":"Overview on the Role of E-Cadherin in Gastric Cancer: Dysregulation and Clinical Implications","volume":"8","author":"Zhao","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol."},{"doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2014). Comprehensive molecular characterization of gastric adenocarcinoma. Nature, 513, 202\u2013209.","key":"ref_93","DOI":"10.1038\/nature13480"},{"doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2017). Integrated genomic characterization of oesophageal carcinoma. Nature, 541, 169\u2013175.","key":"ref_94","DOI":"10.1038\/nature20805"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/18\/4591\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:01:44Z","timestamp":1760166104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/18\/4591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,13]]},"references-count":94,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["cancers13184591"],"URL":"https:\/\/doi.org\/10.3390\/cancers13184591","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2021,9,13]]}}}